Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 356,500 shares, a decline of 11.0% from the December 15th total of 400,500 shares. Currently, 2.2% of the shares of the company are sold short. Based on an average daily volume of 165,700 shares, the short-interest ratio is currently 2.2 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Immix Biopharma in a research report on Monday, January 6th.

Immix Biopharma Stock Down 1.0 %

Shares of Immix Biopharma stock traded down $0.02 during mid-day trading on Friday, hitting $2.04. The stock had a trading volume of 121,030 shares, compared to its average volume of 140,296. The firm has a 50-day moving average of $2.07 and a two-hundred day moving average of $1.95. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $5.73. The firm has a market cap of $56.12 million, a P/E ratio of -2.40 and a beta of 0.27.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). Sell-side analysts expect that Immix Biopharma will post -0.74 earnings per share for the current year.

Institutional Investors Weigh In On Immix Biopharma

Several institutional investors have recently modified their holdings of IMMX. FNY Investment Advisers LLC acquired a new stake in Immix Biopharma during the 4th quarter worth $63,000. Geode Capital Management LLC raised its stake in Immix Biopharma by 5.6% during the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock worth $224,000 after acquiring an additional 7,954 shares in the last quarter. Finally, Invst LLC acquired a new stake in Immix Biopharma during the 2nd quarter worth $57,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.